Imara Overview
- Year Founded
-
2016
- Status
-
Acquired/Merged
- Employees
-
6
- Latest Deal Type
-
M&A
- Latest Deal Amount
-
$34.5M
Imara General Information
Description
Developer of novel therapeutics designed to treat patients with sickle cell disease and other hemoglobinopathies. The company is focused on developing and commercializing novel therapeutics to treat patients with rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies, and other serious diseases, and on its product candidate, tovinontrine (IMR-687), enabling people to get a cure for their illness.
Contact Information
Website
www.imaratx.comCorporate Office
- 116 Huntington Avenue
- 6th Floor
- Boston, MA 02116
- United States
Corporate Office
- 116 Huntington Avenue
- 6th Floor
- Boston, MA 02116
- United States
Imara Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 5. Merger/Acquisition | 23-Feb-2023 | $34.5M | Completed | Profitable | ||
| 4. IPO | 12-Mar-2020 | Completed | Clinical Trials - Phase 2 | |||
| 3. Early Stage VC (Series B) | 01-Feb-2020 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series A) | 14-Apr-2016 | $31M | $34M | Completed | Clinical Trials - Phase 1 | |
| 1. Seed Round | 26-Jan-2016 | $3M | $3M | Completed | Clinical Trials - Phase 1 |
Imara Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A | ||||||||
| Seed | 2,712,960 | $0.001000 | 8% | $1 | $1 | 1x | $1 | 2.73% |
Imara Comparisons
Industry
Financing
Details
Imara Competitors (80)
One of Imara’s 80 competitors is Inovio Pharmaceuticals, a Corporation company based in Plymouth Meeting, PA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Sangamo Therapeutics | Formerly VC-backed | Richmond, CA | ||||
| Immunitas Therapeutics | Formerly VC-backed | Boston, MA | ||||
| Taysha Gene Therapies | Formerly VC-backed | Dallas, TX |
Imara Signals
Imara Former Investors (10)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Alexandria Venture Investments | Venture Capital | Minority | ||
| Arix Bioscience | Venture Capital | Minority | ||
| Bay City Capital | Venture Capital | Minority | ||
| Lundbeckfonden BioCapital | Venture Capital | Minority | ||
| NB Ventures | Venture Capital | Minority |
Imara Investments & Acquisitions (3)
Imara’s most recent deal was a Reverse Merger with Enliven Therapeutics for . The deal was made on 23-Feb-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Enliven Therapeutics | 23-Feb-2023 | Reverse Merger | Drug Discovery | ||
| Complexa (Activator of Nuclear Factor Erythroid 2-Related Factor 2 Drug) | 01-Oct-2020 | Corporate Asset Purchase | Buildings and Property | ||
| Lundbeck (Exclusive Worldwide License To IMR-687, A Hemoglobinopathy Drug) | 16-Apr-2016 | Corporate Asset Purchase | Buildings and Property |
Imara ESG
Risk Overview
Risk Rating
Updated November, 04, 2026
37.76 | High Risk
Risk Scale
A lower score indicates better sustainability
Negl
0-10
Low
10-20
Med
20-30
High
30-40
Severe
40+
Exposure
Exposure refers to the extent to which a company is exposed to different material ESG issues
Management
Management is related to actions taken to manage ESG issues
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
of 13,592
Rank
Percentile
Pharmaceuticals
Industry
of 852
Rank
Percentile
Biotechnology
Subindustry
of 431
Rank
Percentile
Imara FAQs
-
When was Imara founded?
Imara was founded in 2016.
-
Where is Imara headquartered?
Imara is headquartered in Boston, MA.
-
What is the size of Imara?
Imara has 6 total employees.
-
What industry is Imara in?
Imara’s primary industry is Drug Discovery.
-
Is Imara a private or public company?
Imara is a Private company.
-
What is the current valuation of Imara?
The current valuation of Imara is .
-
What is Imara’s current revenue?
The current revenue for Imara is .
-
How much funding has Imara raised over time?
Imara has raised $189M.
-
Who are Imara’s investors?
Alexandria Venture Investments, Arix Bioscience, Bay City Capital, Lundbeckfonden BioCapital, and NB Ventures are 5 of 10 investors who have invested in Imara.
-
Who are Imara’s competitors?
Inovio Pharmaceuticals, Prevail Therapeutics, Sangamo Therapeutics, Immunitas Therapeutics, and Taysha Gene Therapies are some of the 80 competitors of Imara.
-
When was Imara acquired?
Imara was acquired on 23-Feb-2023.
-
Who acquired Imara?
Imara was acquired by Enliven Therapeutics.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process